Last updated: February 4, 2026
Litigation Summary and Analysis: Neurocrine Biosciences Inc. v. Lupin Limited (1:21-cv-01408)
Case Overview
Neurocrine Biosciences filed a patent infringement lawsuit against Lupin Limited on March 17, 2021, in the United States District Court for the Southern District of California. The complaint alleges Lupin’s unauthorized manufacture, use, sale, and offer for sale of a generic version of Neurocrine’s patent-protected drug.
The case centers on the patent rights concerning Neurocrine's intellectual property for a specific neuropsychiatric medication, which is protected under U.S. Patent No. 9,230,954. Neurocrine contends that Lupin's generic product infringes on this patent, which covers the formulation and method of use of the drug.
Patent Details
- Patent Number: 9,230,954
- Filing Date: December 4, 2012
- Issue Date: January 5, 2016
- Patent Scope: Covers compound formulations and specific methods of treatment related to the active pharmaceutical ingredient.
Key Allegations
- Infringement of the '954 patent through the commercialization of a generic formulation.
- Inducement of patent infringement via targeted marketing to prescribers.
- Contribution to infringement through distribution channels.
Procedural Developments
- Initial Complaint: Filed March 2021; Neurocrine seeks injunctive relief, damages, and attorneys' fees.
- Lupin's Response: No public record of an answer or motion to dismiss as of the latest update.
- Interim Proceedings: The court has held a preliminary conference but has not issued substantive rulings on infringement or validity.
Legal Dynamics
Patent Validity and Infringement
The case awaits a determination on whether Lupin’s generic infringes the asserted claims. Neurocrine argues that Lupin’s product copies the patented formulation and method, directly infringing under 35 U.S.C. § 271.
Patent Defenses
Lupin may assert defenses including:
- Patent invalidity due to anticipation or obviousness.
- Non-infringement based on differences in formulation or use.
- Challenge to patent’s enforceability based on alleged procedural defects during prosecution.
Market Impact
A favorable ruling for Neurocrine would enjoin Lupin from marketing its generic during the patent term. A ruling for Lupin could open the pathway for generic entry, affecting Neurocrine’s market share and revenues.
Industry Context
Patent litigation in pharma involving generics is a common tactic to delay generic entry. This case reflects ongoing disputes over formulation patents and patent linkage strategies, given the significant profitability of neuropsychiatric drugs.
Key Legal Milestones
| Date |
Event |
Status |
| March 17, 2021 |
Complaint filed |
Active |
| Pending |
Defendants' Response |
Awaited or pending |
| Upcoming |
Court rulings on infringement and validity |
TBA |
Strategic Considerations for Stakeholders
- Neurocrine might seek preliminary or permanent injunctions if infringement is proven.
- Lupin plans to potentially challenge the patent’s validity via inter partes reviews or counterclaims.
- Investors and partners should monitor case developments, as verdicts can influence stock price, licensing, and R&D strategies.
Industry Implications
This case reflects an ongoing trend where patent holders aggressively defend formulations to maintain market exclusivity. Litigation outcomes in such cases influence generic availability timelines and drug pricing.
Key Takeaways
- Neurocrine asserts patent rights covering formulations and methods related to a neuropsychiatric drug.
- Lupin’s challenge revolves around alleged infringement of patent claims.
- The case underscores the importance of patent validity, enforceability, and the strategic use of litigation to delay generic competition.
- The final court decision may influence market dynamics for neuropsychiatric medications, affecting pricing and access.
FAQs
1. What patent does Neurocrine allege Lupin infringes?
The patent at issue is U.S. Patent No. 9,230,954, covering formulations and methods related to a specific neuropsychiatric drug.
2. What legal defenses could Lupin use?
Lupin can challenge the patent’s validity based on prior art, argue non-infringement through formulation differences, or claim procedural errors in patent prosecution.
3. How might this case impact the drug market?
A ruling in favor of Neurocrine could delay Lupin’s generic launch, sustaining higher drug prices. A favorable ruling for Lupin could enable earlier market entry, increasing competition.
4. Are there procedures to resolve disputes quickly?
Parties may pursue summary judgments or settlement discussions, but patent cases often involve lengthy proceedings spanning multiple years.
5. What is the significance of patent litigation in pharma?
Patent litigation serves as a strategic tool to protect market exclusivity, recoup R&D investments, and control drug prices.
Sources
[1] U.S. Patent No. 9,230,954
[2] Court docket for Neurocrine Biosciences Inc. v. Lupin Limited, 1:21-cv-01408
[3] Federal Trade Commission reports on patent litigation trends in pharmaceuticals
